A clinical study on docetaxel combined with nedaplatin or cisplantin in the treatment of advanced head and neck carcinoma
10.3760/cma.j.issn.1008-6706.2012.18.002
- VernacularTitle:多西他赛联合奈达铂或顺铂治疗中晚期头颈部肿瘤的临床观察
- Author:
Hao LIU
;
Ying DENG
;
Ke XIE
;
Honglin HU
- Publication Type:Journal Article
- Keywords:
Head and neck neoplasms;
Docetaxel;
Cisplatin;
Nedaplatin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2012;19(18):2723-2724
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and toxicity of the docetaxel combined with nedaplatin or cisplatin in the treatment of patients with advanced head and neck carcinoma.Methods 58 patients with advanced head and neck carcinoma were enrolled into the study.These patients were divided into nedaplatin group (27 patients:docetaxel 75mg/m2 on day 1 and nedaplatin 80mg/m2 on day 1 of the 21-day cycle) and cisplantin group( 31 patients:docetaxel 75mg/m2 on day 1 and cisplatin 25mg/m2 on day 1-3 day of 21-day cycle).Each patient should complete two cycle.Results The response rate in nedaplatin group was 59.2％ and in cisplantin group was 54.8％,the difference was statistically significant between the two groups( P ＞ 0.05 ).The rate of white blood cell and plate let reduction in nedaplatin group was 55.5％,40.7％,respectively,and those in cisplantin group was 51.6％,35.4％,respectively,the difference was statistically significant between the two groups ( call P ＜ 0.05 ).The rate of vomit in nedaplatin group was 29.6％,which was lower than that of cisplantin group (64.5％) ( x2 =4.02,P ＜ 0.05 ).Conclusion In the treatment of advanced head and neck carcinoma,the combination of docetaxel and nedaplatin had the same efficacy as the combination of docetaxel and cisplatin,and they appeared to be more-tolerated.
